GlassScriptPhysician profile
Amanda J Backlund
NPI 1114153301
$2,566.14
in general payments reported to CMS, 2019-2025
37 companies · $638 in 2025
The $638 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $53.00 · 2021: $296 · 2022: $174 · 2023: $536 · 2024: $642 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.49 | 2021-2025 | Viberzi, Linzess, Vraylar |
| Novo Nordisk INC | $332.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $317.54 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $268.39 | 2023-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $203.21 | 2023-2025 | |
| Astellas Pharma US INC | $143.72 | 2020-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $75.19 | 2023-2024 | Farxiga |
| Tris Pharma INC | $69.01 | 2024-2025 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $55.56 | 2022-2024 | Rexulti, Nuedexta |
| Supernus Pharmaceuticals, INC. | $55.43 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.42 | 2019-2023 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $46.97 | 2019 | |
| Harmony Biosciences LLC | $41.91 | 2023 | Wakix |
| Axsome Therapeutics, INC. | $41.89 | 2024-2025 | Auvelity |
| Abbott Laboratories | $39.98 | 2024 | Freestyle Libre 3 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Backlund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.